Morgan Stanley resumes coverage of Pfizer (PFE +0.1% to $28.37) at Overweight and gives the...


Morgan Stanley resumes coverage of Pfizer (PFE +0.1% to $28.37) at Overweight and gives the company a price target of $31.00. The rating comes as the EU authorizes the expanded use of Pfizer's blockbuster anti-bacterial vaccine Prevenar 13. Thirteen analysts rate Pfizer a Buy, six a Hold and two a Sell.

From other sites
Comments (1)
  • Ed Rudy, WWW.EdRudy.com
    , contributor
    Comments (738) | Send Message
     
    Morgan Stanley coverage, precipitated by approval of Pfizer's new blockbuster drug PROVENAR, will add to the upward impetus of Pfizer's price and dividends.
    Buy Pfizer (PFE).
    10 Jul 2013, 09:54 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs